(Q33175457)

23 July 2017

0 references

Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias (English)

1 reference

23 July 2017

0 references

Simons GR

1

1 reference

23 July 2017

Eisenstein EL

2

1 reference

23 July 2017

Shaw LJ

3

1 reference

23 July 2017

Mark DB

4

1 reference

23 July 2017

Pritchett EL

5

1 reference

23 July 2017

language of work or name

English

0 references

publication date

1 December 1997

1 reference

American Journal of Cardiology

23 July 2017

published in

1 reference

23 July 2017

volume

80

1 reference

23 July 2017

issue

12

1 reference

23 July 2017

page(s)

1551-1557

1 reference

Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs

23 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Antiarrhythmic drugs: a possible cause of out-of-hospital cardiac arrest

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Sotalol, hypokalaemia, syncope, and torsade de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Arrhythmogenic effects of antiarrhythmic drugs: a study of 506 patients treated for ventricular tachycardia or fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Clinical safety profile of sotalol in the treatment of arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Meta-analytic tools for medical decision making: a practical guide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Oral propafenone therapy for patients with paroxysmal supraventricular tachyarrhythmia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. dl-Sotalol Atrial Fibrillation Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Safety and efficacy of oral flecainide therapy in patients with atrioventricular re-entrant tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Quinidine treatment of chronic lone atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Direct current conversion of atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. A controlled clinical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Electrophysiologic and clinical effects of flecainide for recurrent paroxysmal supraventricular tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Propafenone for prevention of recurrent atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Electrophysiologic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Randomized comparison of flecainide and cibenzoline in the conversion of atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Wavelength index: a predictor of the response to disopyramide in paroxysmal lone atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Combined treatment of atrial fibrillation with quinidine and beta-blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Efficacy of sotalol in controlling reentrant supraventricular tachycardias.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Efficacy of disopyramide in conversion and prophylaxis of post-thyrotoxic atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Comparative efficacy of short-acting and long-acting quinidine for maintenance of sinus rhythm after electrical conversion of atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Therapeutic efficacy and safety of oral propafenone for atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Long-term results of DC reversion of atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Paroxysmal supraventricular tachycardia: experience with propafenone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Effect of quinidine on digoxin concentration in skeletal muscle and serum in patients with atrial fibrillation. Evidence for reduced binding of digoxin in muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. The Sotalol Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Long-term efficacy of flecainide in paroxysmal atrial fibrillation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Conversion of chronic atrial fibrillation to sinus rhythm with combined propranolol and quinidine treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Direct current shock and antidysrhythmic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Flecainide acetate in the treatment of supraventricular tachycardias: Value of programmed electrical stimulation for long-term prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Combined propranolol and quinidine treatment in cardiac arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Clinical course of recent-onset atrial fibrillation treated with oral propafenone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

"Late" proarrhythmia due to quinidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Proarrhythmia in patients treated for atrial fibrillation or flutter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

An analysis of the cost effectiveness of the implantable defibrillator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

Cost-effectiveness of the implantable cardioverter-defibrillator: Effect of improved battery life and comparison with amiodarone therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900773-X

10.1016/S0002-9149(97)00773-X

7 January 2021

Identifiers

DOI

1 reference

23 July 2017

1 reference